Having determined the preferential expression of EphA3 on tumour adjacent bone marrow-derived mesenchymal (BMSCs), myeloid and vascular cells, the effect of a chimeric EphA3 agonistic antibody (chIIIA4) was investigated in mouse xenograft models of colon and prostate carcinoma [137]. Here, EPHA3 is linked to prostate carcinoma.